WASHINGTON, July 8, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service for individual investors, today announced that the service's model portfolio delivered a return of 48.6% in the first six months of 2003.
Growth Report has followed 27 companies during the first half of the year. The model portfolio is currently comprised of 21 companies, while six positions have been closed thus far this year. The Growth Report model portfolio tracks the performance of the stocks followed by the newsletter service. In 2003, Growth Report added ten new companies to the portfolio, the average of which returned 40.5% from the initial date of coverage through June 30th.
"Our purchase of Internet stocks including Bankrate (Nasdaq:RATE) +1,052%, Internet Gold (Nasdaq:IGLD) +45%, j2 Global Communications (Nasdaq:JCOM) +324%, FindWhat (Nasdaq:FWHT) +311%, and NetFlix (Nasdaq:NFLX) +58% in 2002 has continued to yield strong returns into the first half of 2003," commented Ian Wyatt, Editor-in-Chief of Growth Report.
He went on to say, "Another sector that has performed very well for us has been generic and specialty pharmaceuticals. Our recent Special Report on the sector titled "Not So Unique Returns -- Investing in Generic and Specialty Pharmaceuticals" provides in-depth information on three companies in this sector -- aaiPharma (Nasdaq:AAII) +38%, Bentley Pharmaceuticals (AMEX:BNT) +47%, and Impax Laboratories (Nasdaq:IPXL) +39%."
Free trial and paid subscribers can view Growth Report's current comments on these companies and receive this Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals" on the Internet at http://www.growthreport.com
Growth Report's stock portfolio returned 40% in 2002, and is up another 48.6% in the first half of 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach had yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive the free Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals." Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr3
About Growth Report
Growth Report is a leading investment newsletter service published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.